ERBB2 and breast carcinoma: In the VERITAC trial, ARV-471, as a monotherapy for advanced or metastatic ER+/HER2- breast cancer patients, demonstrated good tolerability and a 38% clinical benefit rate (including complete response, partial response, or disease stabilization for more than 24 weeks).